Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
Authors:
- Julia E ClarkJCJulia E Clark
- Paediatric Active Enhanced Disease Surveillance (Paeds)P(Paediatric Active Enhanced Disease Surveillance (Paeds)
- Elizabeth ElliottEEElizabeth Elliott
- 21 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (6) , 940-948
Abstract
In 2017, Australia experienced record influenza notifications. Two surveillance programs combined to summarize the epidemiology of hospitalized influenza in children and report on vaccine effectiveness (VE) in the context of a limited nationally funded vaccination program. Subjects were prospectively recruited (April-October 2017). Case patients were children aged ≤16 years admitted to 11 hospitals with an acute respiratory illness and laboratory-confirmed influenza. Controls were hospitalized with acute respiratory illness and tested negative for influenza. VE estimates were calculated using the test-negative design. A total of 1268 children were hospitalized with influenza: 31.5% were <2 years old, 8.3% were indigenous, and 45.1% had comorbid conditions predisposing to severe influenza. Influenza B was detected in 34.1% with influenza A/H1N1 and A/H3N2 detected in 47.2% and 52.8% of subtyped influenza A specimens. The median length of stay was 3 days (interquartile range, 1-5), 14.5% were admitted to the intensive care unit, and 15.9% received oseltamivir. Four in-hospital deaths occurred (0.3%): one was considered influenza associated. Only 17.1% of test-negative-controls were vaccinated. The VE of inactivated quadrivalent influenza vaccine for preventing hospitalized influenza was estimated at 30.3% (95% confidence interval, 2.6%-50.2%). Significant influenza-associated morbidity was observed in 2017 in Australia. Most hospitalized children had no comorbid conditions. Vaccine coverage and antiviral use was inadequate. Influenza vaccine was protective in 2017, yet VE was lower than previous seasons. Multiple Australian states have introduced funded preschool vaccination programs in 2018. Additional efforts to promote vaccination and monitor effectiveness are required.Keywords
Funding Information
- National Health and Medical Research Council (APP1113851)
This publication has 28 references indexed in Scilit:
- Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010–11 Seasons: A Test-negative Observational StudyPLOS ONE, 2013
- Paediatric Active Enhanced Disease Surveillance: A new surveillance system for AustraliaJournal of Paediatrics and Child Health, 2013
- Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling studyThe Lancet Infectious Diseases, 2012
- Trivalent influenza vaccine and febrile adverse events in Australia, 2010: Clinical features and potential mechanismsVaccine, 2011
- Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccineBMJ Open, 2011
- Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young ChildrenThe Pediatric Infectious Disease Journal, 2011
- Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory‐confirmed influenza in hospitalised children aged 6–59 monthsInfluenza and Other Respiratory Viruses, 2010
- Effect of Influenza Vaccination of Children on Infection Rates in Hutterite CommunitiesJAMA, 2010
- The Australian Childhood Immunisation Register—A model for universal immunisation registers?Vaccine, 2009
- Assessment of the Protective Efficacy of Vaccines against Common Diseases Using Case-Control and Cohort StudiesInternational Journal of Epidemiology, 1984